CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01186328
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:59.628723+00:00
Published At: 2019-07-24T00:00:00+00:00
Record Updated At: 2024-02-01
Results Posted At: 2019-07-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoblastic Leukemia, Acute", "Lymphoblastic Leukemia, Acute, Childhood", "Leukemia, Lymphoblastic, Acute, T Cell", "Leukemia, Lymphoblastic, Acute"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-02-01"
protocolSection.identificationModule.nctId: "NCT01186328"
protocolSection.identificationModule.officialTitle: "A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-07-24"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.